Business Description
Hansoh Pharmaceutical Group Co Ltd
ISIN : KYG549581067
Compare
Compare
Traded in other countries / regions
03692.Hong Kong3KY.GermanyHNSPF.USA IPO Date
2019-06-14Description
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.78 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | 1.07 | |||||
| Interest Coverage | 42.58 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.23 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.1 | |||||
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | -2.5 | |||||
| 3-Year FCF Growth Rate | -6 | |||||
| 3-Year Book Growth Rate | 19.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 12.13 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.27 | |||||
| 9-Day RSI | 70.2 | |||||
| 14-Day RSI | 66.8 | |||||
| 6-1 Month Momentum % | 15.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.21 | |||||
| Quick Ratio | 4.12 | |||||
| Cash Ratio | 3.62 | |||||
| Days Inventory | 192.79 | |||||
| Days Sales Outstanding | 121.94 | |||||
| Days Payable | 81.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.74 | |||||
| Dividend Payout Ratio | 0.22 | |||||
| Forward Dividend Yield % | 1.3 | |||||
| 5-Year Yield-on-Cost % | 0.74 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 0.66 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.8 | |||||
| Operating Margin % | 28.1 | |||||
| Net Margin % | 32.44 | |||||
| FCF Margin % | 18.29 | |||||
| ROE % | 13.45 | |||||
| ROA % | 10.28 | |||||
| ROIC % | 26.74 | |||||
| ROC (Joel Greenblatt) % | 83.72 | |||||
| ROCE % | 14.62 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 29.6 | |||||
| PE Ratio without NRI | 30.45 | |||||
| Price-to-Owner-Earnings | 42.74 | |||||
| PEG Ratio | 3.21 | |||||
| PS Ratio | 9.19 | |||||
| PB Ratio | 3.54 | |||||
| Price-to-Tangible-Book | 3.56 | |||||
| Price-to-Free-Cash-Flow | 49.53 | |||||
| Price-to-Operating-Cash-Flow | 42.85 | |||||
| EV-to-EBIT | 17.87 | |||||
| EV-to-EBITDA | 17.04 | |||||
| EV-to-Revenue | 6.78 | |||||
| EV-to-FCF | 34.12 | |||||
| Price-to-Peter-Lynch-Fair-Value | 3.62 | |||||
| Price-to-Graham-Number | 2.2 | |||||
| Price-to-Net-Current-Asset-Value | 4.22 | |||||
| Price-to-Net-Cash | 5.18 | |||||
| Earnings Yield (Greenblatt) % | 5.6 | |||||
| FCF Yield % | 2.02 | |||||
| Forward Rate of Return (Yacktman) % | 11.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hansoh Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 11,051.337 | ||
| EPS (TTM) (HK$) | 0.569 | ||
| Beta | 0.88 | ||
| Volatility % | 57.9 | ||
| 14-Day RSI | 66.8 | ||
| 14-Day ATR (HK$) | 0.646772 | ||
| 20-Day SMA (HK$) | 15.77 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (HK$) | 9.41 - 17.24 | ||
| Shares Outstanding (Mil) | 5,930.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hansoh Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hansoh Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hansoh Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Hansoh Pharmaceutical Group Co Ltd(HKSE:03692)'s stock price today?
The current price of HKSE:03692 is HK$16.84. The 52 week high of HKSE:03692 is HK$17.24 and 52 week low is HK$9.41.
When is next earnings date of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692)?
The next earnings date of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) is .
Does Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) pay dividends? If so, how much?
The Dividend Yield %  of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) is 0.74% (As of Today), Highest Dividend Payout Ratio of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) was 0.28. The lowest was 0.14. And the median was 0.21. The  Forward Dividend Yield % of Hansoh Pharmaceutical Group Co Ltd(HKSE:03692) is 1.3%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers